CareDx CDNA shares rallied 6.1% in the last trading session to close at $25.07. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session.

CareDx CDNA shares ended the last trading session 11.2% higher at $24.91. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session.

Prudential Financial Inc. boosted its position in shares of CareDx, Inc (NASDAQ:CDNA – Free Report) by 58.5% in the 4th quarter, according to the company in its most recent 13F filing with the ...

CareDx, Inc (NASDAQ:CDNA – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the seven research firms that are currently covering the stock, MarketBeat.com reports. Three ...

In a report released yesterday, Mark Massaro from BTIG reiterated a Buy rating on CareDx (CDNA – Research Report), with a price target of ...

BRISBANE, Calif., March 11, 2025--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of ...

CareDx (CDNA) reported $86.58 million in revenue for the quarter ended December 2024, representing a year-over-year increase of 32%. EPS of $0.18 for the same period compares to -$0.17 a year ago.

The MI355X, now expected to arrive by mid-2025, is manufactured on TSMC’s 3nm node and built on AMD's new CDNA 4 architecture ...

The new MessageBOOSTER cDNA Synthesis from Cell Lysates kit eliminates these difficulties by enabling RNA amplification and cDNA synthesis directly from cell lysates, without the need to purify ...

Epicentre's Message BOOSTER ™ cDNA Synthesis from Cell Lysates kit enables RNA amplification and cDNA synthesis directly from cell lysates. A Message BOOSTER kit reaction from a single cell ...